Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GRETEL TRULLENQUE

Allopathic & Osteopathic Physicians Family Medicine

NPI
1720076144
CMS profile
32746
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,220.64

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $989.23 2
Food and Beverage $231.41 3

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $1,204.08 4
AstraZeneca Pharmaceuticals LP $16.56 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GRETEL TRULLENQUE

NPI 1720076144 · CMS profile ID 32746

Allopathic & Osteopathic Physicians / Family Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720076144?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GRETEL TRULLENQUE, NPI 1720076144, CMS profile ID 32746. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720076144?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). GRETEL TRULLENQUE, NPI 1720076144, CMS profile ID 32746. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720076144?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
GRETEL TRULLENQUE, NPI 1720076144, CMS profile ID 32746, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1720076144?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $1,220.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $16.5605/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206648462 CMS
Novartis Pharmaceuticals Corporation $74.9301/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200581425 CMS
Novartis Pharmaceuticals Corporation $299.2501/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200581421 CMS
Novartis Pharmaceuticals Corporation $139.9201/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200581423 CMS
Novartis Pharmaceuticals Corporation $689.9801/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200581427 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,374.49 69
PY2020 $1,355.75 79
PY2021 $259.48 14
PY2022 $192.27 9
PY2023 $2,004.82 9
PY2024 $1,983.09 17
PY2025 $1,220.64 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,629,687.56 10
PY2024 Principal investigator $1,001,480.43 22
PY2023 Principal investigator $393,727.30 31
PY2022 Principal investigator $743,619.78 33
PY2021 Principal investigator $102,847.74 117
PY2020 Principal investigator $1,098,095.92 216
PY2019 Principal investigator $335,867.48 106

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

117 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $27,218.00 12/20/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults No dispute reported 06/30/2026 787662381
Principal investigator 1 ABBVIE INC. $589.40 12/09/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792486223
Principal investigator 1 ABBVIE INC. $2,849.40 10/07/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792478081
Principal investigator 1 ABBVIE INC. $6,114.50 09/08/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792474265
Principal investigator 1 ABBVIE INC. $63.70 07/29/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792469421
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 07/16/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789144505
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $250.00 07/16/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789153831
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $250.00 07/16/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789154737
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 07/16/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789155811
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 07/16/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789155893
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 06/07/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789134389
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $150.00 06/07/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789141717
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $150.00 06/07/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789154259
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 06/07/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789154971
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 06/07/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789155355
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $150.00 06/07/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789155639
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 06/07/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789155983
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $150.00 06/07/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789156235
Principal investigator 1 ABBVIE INC. $4,685.40 05/27/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792460209
Principal investigator 1 Incyte Corporation $3,185.00 04/30/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 831147313
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $250.00 04/08/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789151207
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $250.00 04/08/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789152005
Principal investigator 1 ABBVIE INC. $7,835.00 03/30/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792436645
Principal investigator 1 Incyte Corporation $744.29 03/26/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis No dispute reported 06/30/2026 831147311
Principal investigator 1 ABBVIE INC. $92.00 03/08/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792432475
Principal investigator 1 ABBVIE INC. $1,743.30 03/02/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792427497
Principal investigator 1 ABBVIE INC. $43.00 02/18/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792424203
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 02/10/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789153527
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,429.20 02/03/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789151507
Principal investigator 1 ABBVIE INC. $64.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419469
Principal investigator 1 ABBVIE INC. $64.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419475
Principal investigator 1 ABBVIE INC. $64.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419481
Principal investigator 1 ABBVIE INC. $128.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419487
Principal investigator 1 ABBVIE INC. $128.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419493
Principal investigator 1 ABBVIE INC. $128.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419499
Principal investigator 1 ABBVIE INC. $128.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419503
Principal investigator 1 ABBVIE INC. $64.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419511
Principal investigator 1 ABBVIE INC. $64.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419516
Principal investigator 1 ABBVIE INC. $64.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419521
Principal investigator 1 ABBVIE INC. $64.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419527
Principal investigator 1 ABBVIE INC. $64.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419533
Principal investigator 1 ABBVIE INC. $64.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419539
Principal investigator 1 ABBVIE INC. $43.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419545
Principal investigator 1 ABBVIE INC. $86.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419551
Principal investigator 1 ABBVIE INC. $43.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419557
Principal investigator 1 ABBVIE INC. $43.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419563
Principal investigator 1 ABBVIE INC. $43.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419569
Principal investigator 1 ABBVIE INC. $3,000.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419575
Principal investigator 1 ABBVIE INC. $5,000.00 02/01/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419581
Principal investigator 1 ABBVIE INC. $4,648.30 01/28/2021 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792413937
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $500.00 01/22/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789137835
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $212.00 01/21/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789146789
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $371.00 01/20/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789153379
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789128893
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789130343
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $200.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789133093
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789135537
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789136685
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $318.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789140859
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $200.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789143233
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $159.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789147743
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $159.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789152429
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $106.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789153039
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $477.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789154515
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $200.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789154857
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789155455
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789155549
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789156073
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $200.00 01/19/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 789156155
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 01/15/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789127419
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 01/15/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789142499
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,167.00 01/15/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789143923
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 01/15/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789145117
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 01/15/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789148213
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,167.00 01/15/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789149057
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,792.00 01/15/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789150894
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 01/15/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789152645
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 01/15/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789152847
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 01/15/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789153675
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,167.00 01/15/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789154125
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,167.00 01/15/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789154391
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $375.00 01/15/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789154629
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 01/15/2021 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II Randomized Double Blind Placebo Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 787662401
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 01/15/2021 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II Randomized Double Blind Placebo Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 787662548
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $150.00 01/07/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789146259
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 01/07/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789153981
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $100.00 01/07/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789155077
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $150.00 01/07/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789155721
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $100.00 01/07/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789156313
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $100.00 01/06/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789131745
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $150.00 01/06/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789145703
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $150.00 01/06/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789147275
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $150.00 01/06/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789149461
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $100.00 01/06/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789149845
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $100.00 01/06/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789150217
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 01/06/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789151761
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 01/06/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789153217
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $150.00 01/06/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789155177
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 01/06/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789155273
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 01/05/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789125951
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $265.00 01/05/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789138911
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $318.00 01/05/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789139913
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $371.00 01/05/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789148655
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $250.00 01/05/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789150567
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $371.00 01/05/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789152221
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $318.00 01/05/2021 Non-covered Recipient Entity
Floridian Research Institute Llc
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789156389
Principal investigator 1 Janssen Research & Development, LLC $150.00 01/01/2021 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II Randomized Double Blind Placebo Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 787662421
Principal investigator 1 Janssen Research & Development, LLC $150.00 01/01/2021 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II Randomized Double Blind Placebo Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 787662439
Principal investigator 1 Janssen Research & Development, LLC $150.00 01/01/2021 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II Randomized Double Blind Placebo Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 787662459
Principal investigator 1 Janssen Research & Development, LLC $150.00 01/01/2021 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II Randomized Double Blind Placebo Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 787662476
Principal investigator 1 Janssen Research & Development, LLC $150.00 01/01/2021 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II Randomized Double Blind Placebo Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 787662493
Principal investigator 1 Janssen Research & Development, LLC $150.00 01/01/2021 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II Randomized Double Blind Placebo Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 787662511
Principal investigator 1 Janssen Research & Development, LLC $2,481.25 01/01/2021 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
Dermatitis A Phase II Randomized Double Blind Placebo Controlled Study of Bermekimab in Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 787662529
Principal investigator 1 Janssen Research & Development, LLC $150.00 01/01/2021 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II Randomized Double Blind Placebo Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 787662565
Principal investigator 1 Janssen Research & Development, LLC $50.00 01/01/2021 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II Randomized Double Blind Placebo Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 787662581
Principal investigator 1 Janssen Research & Development, LLC $150.00 01/01/2021 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II Randomized Double Blind Placebo Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 787662601
Principal investigator 1 Janssen Research & Development, LLC $150.00 01/01/2021 Non-covered Recipient Entity
Floridian Rsrch Institute, Llc
A Phase II Randomized Double Blind Placebo Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 787662619